Biomarkers Market - ([Discovery Technologies - Proteomics, Genomics, Imaging, Bioinformatics], Validation Services, Applications [drug development, personalized medicine], Diseases [Oncology, Cardiology, Neurology]) - Global Trends & Forecasts (2013-2018)

世界のバイオマーカー市場

◆タイトル:Biomarkers Market - ([Discovery Technologies - Proteomics, Genomics, Imaging, Bioinformatics], Validation Services, Applications [drug development, personalized medicine], Diseases [Oncology, Cardiology, Neurology]) - Global Trends & Forecasts (2013-2018)
◆商品コード:BT 2120
◆調査・発行会社:MarketsandMarkets
◆発行日:2013年9月
◆ページ数:327
◆レポート形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single userUSD5,650 ⇒換算¥610,200見積依頼/購入/質問フォーム
Multi User(~5名)USD6,650 ⇒換算¥718,200見積依頼/購入/質問フォーム
Corporate licence(社内共有可) USD8,150 ⇒換算¥880,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"世界のバイオマーカー市場"について調査・分析し、イントロダクション、エグゼクティブサマリー、市場概観、市場の成長要因、阻害要因、市場の機会と課題、市場規模及び予測、競争状況、主要企業(ベンダー)分析等の情報をお届けいたします。

A biomarker is an identifiable and measurable characteristic, which identifies the severity and/or occurrence of a specific disease. It has major applications in the discovery and development of novel therapeutic drugs. The global biomarkers market shows a high growth potential and accounts for $17.5 billion in 2013. It is expected to grow at a CAGR of 18.5% from 2013 to 2018, to reach $40.8 billion by 2018.

Advancements in discovery technologies, high demand from the indications of various diseases, increasing partnerships and collaborations to boost biomarker research activities, increase in government and private sector investments and funds for biomarker discovery, FDA support for biomarker development, and increasing utility of biomarkers in patient stratification and drug development process are the major drivers slated to propel the growth of this market. However, a few pivotal factors such as the high capital investment and low benefit-cost ratio, cumbersome biomarker validation procedure, and difficulty in sample collection and its storage are expected to hamper the growth of this market.

The global market has been segmented into discovery technologies, services, applications, and disease indications. The biomarker discovery technology market has been further segmented into omics technology, imaging technology, and bioinformatics. The omics technology segment accounts for the largest share in this market, primarily due to the increase in adoption of proteomics and genomics technologies across the globe.

In addition, the biomarker services (sample preparation, assay development, and biomarker validation and testing) and applications (drug discovery and formulation, and development of molecular diagnostics and personalized medicine) market have also been illustrated in the report. Drug discovery and development segment holds the largest share of biomarker applications market. This is attributed to the potential of biomarkers to reduce the time span of clinical trials, which ultimately decreases the overall cost of the entire drug discovery and development process.

On the basis of type of disease, the global biomarkers market is further classified as oncology, cardiology, neurology, and other diseases (HIV, renal disorders, diabetes, arthritis, and tuberculosis). Oncology biomarkers market accounts for the lion’s share of the biomarker disease indication market and further this market is forecast to grow at the highest growth rate in the next five years. Increasing need for the early diagnosis of tumor cells is the major factor stimulating the growth of oncology market. Oncology biomarkers enhance the screening and early detection of cancer as well as facilitate the high-speed, non-invasive cancer diagnosis procedure.

The key players in this market are Roche Diagnostics Limited (Switzerland), Johnson & Johnson (U.S.), GlaxoSmithKline, Plc. (U.K.), Siemens Healthcare (Germany), Abbott Laboratories, Inc. (U.S.), GE Healthcare (U.K.), Affymetrix, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Epigenomics AG (Germany), Eisai Co. Ltd. (Japan), Bio-Rad Laboratories, Inc. (U.S.), Eli Lilly and Company (U.S.), Merck & Co. (U.S.), Genomic Health, Inc. (U.S.), and Agilent Technologies Inc. (U.S.)

Scope of the Report

This research report categorizes the global biomarkers market on the basis of discovery technology, services, applications, and disease indications. These markets are broken down into segments and sub-segments, providing value analysis for 2011, 2012, and 2013 as well as forecast up to 2018. Each market is comprehensively analyzed by geography (North America, Europe, Asia-Pacific, and Rest of the World), to provide in-depth information on the global scenario.

By Discovery Technologies

Imaging Technologies
Omics Technologies
Proteomics
Genomics
Transcriptomics
Metabolomics
Bioinformatics

By Services

Sample Preparation
Assay Development
Biomarker Validation and Testing

By Applications

Drug Discovery and Development
Personalized Medicine
Molecular Diagnostics
Other Applications

By Disease Indications

Oncology
Cardiology
Neurology
Others

By Geography

North America
Europe
Asia-Pacific
RoW

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 STAKEHOLDERS
1.4 RESEARCH METHODOLOGY
1.4.1 MARKET SIZE
1.4.2 KEY DATA POINTS FROM SECONDARY SOURCES
1.4.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 MARKET OVERVIEW
3.1 DEFINITION OF BIOMARKERS
3.2 BIOMARKERS & ITS TYPES
3.3 BIOMARKERS MARKET
3.3.1 MARKET SEGMENTATION
3.3.2 CHALLENGES & OPPORTUNITIES
3.3.2.1 Challenges
3.3.2.1.1 Variability
3.3.2.1.2 Ethical considerations & acceptability
3.3.2.2 Opportunities
3.3.2.2.1 Personalized medicine
3.3.2.2.2 Companion diagnostics
3.3.3 DRIVERS & RESTRAINTS
3.3.3.1 Drivers
3.3.3.1.1 High demand boosts the growth of the biomarkers market globally
3.3.3.1.2 Strategic collaborations lead to increasing applications in the market
3.3.3.1.3 Technological advances contribute to growth
3.3.3.1.4 The rising prevalence of the disease forms
3.3.3.1.5 FDA support for biomarkers development
3.3.3.2 Restraints
3.3.3.2.1 Low capital investment & cost-benefit hinders growth of biomarkers
3.3.3.2.2 Biomarkers not a profitable market for small organizations
3.3.3.2.3 Sample collection & storage
3.3.3.2.4 Limited biomarkers validation
3.3.3.2.5 Need for new R&D models with greater precision & flexibility

4 GLOBAL BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES
4.1 INTRODUCTION
4.2 IMAGING TECHNOLOGIES FOR BIOMARKERS DISCOVERY
4.2.1 POSITRON EMISSION TOMOGRAPHY (PET)
4.2.2 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY(SPECT)
4.2.3 ULTRASOUND
4.2.4 MAGNETIC RESONANCE IMAGING (MRI)
4.2.5 COMPUTED TOMOGRAPHY (CT)
4.3 OMICS TECHNOLOGIES FOR BIOMARKERS DISCOVERY
4.3.1 PROTEOMICS
4.3.1.1 Mass spectrometry
4.3.1.1.1 MALDI mass spectrometry
4.3.1.1.2 Imaging mass spectrometry
4.3.1.2 2D Gel Electrophoresis
4.3.1.3 Protein microarray technology
4.3.1.4 Antibody array technology
4.3.1.5 Peptide array technology
4.3.2 GENOMICS
4.3.2.1 Whole genome sequencing
4.3.2.2 Genotyping
4.3.2.3 Epigenetics
4.3.3 TRANSCRIPTOMICS
4.3.3.1 Microarrays
4.3.3.2 Gene expression profiling
4.3.4 METABOLOMICS
4.3.4.1 Capillary electrophoresis
4.3.4.2 Mass spectrometry based kits
4.3.4.3 Nuclear Magnetic Resonance(NMR)
4.4 BIOINFORMATICS
4.4.1 CLUSTER ANALYSIS
4.4.2 STATISTICAL ANALYSIS
4.4.3 CELL SIGNAL PATHWAYS
4.4.4 COMPUTER AIDED DESIGN
4.4.5 DATA MINING
4.4.6 PROTEIN INTERACTION MAPS

5 SERVICES MARKET OF BIOMARKERS
5.1 INTRODUCTION
5.2 CLINICAL
5.2.1 SAMPLE PREPARATION
5.2.2 ASSAY DEVELOPMENT
5.2.3 BIOMARKERS VALIDATION & TESTING
5.2.3.1 Feasibility Studies and choice of assay & biomarkers
5.2.3.2 Long lead time required for Biomarkers Assay preparation
5.3 BIOINFORMATICS
5.3.1 FUNCTIONAL GENOMICS & PROTEOMICS DRIVE THE DEMAND FOR BIOINFORMATICS

6 BIOMARKERS APPLICATION MARKET
6.1 INTRODUCTION
6.2 DRUG DISCOVERY & DEVELOPMENT
6.2.1 CLINICAL TRIALS
6.2.1.1 Preclinical Development
6.2.1.2 Phase I drug development
6.2.1.3 Phase II drug development
6.2.1.4 Phase III drug development
6.2.1.5 Phase IV drug development
6.3 PERSONALIZED MEDICINE
6.4 MOLECULAR DIAGNOSTICS
6.4.1 MOLECULAR DIAGNOSTICS IS A DYNAMIC & RAPIDLY BROADENING MARKET
6.4.2 TRENDS IN THE DIAGNOSTICS MARKET
6.4.3 CHALLENGES
6.4.3.1 Nucleic acids pose a challenge to the molecular diagnostics field
6.4.3.2 Molecular diagnostics market lacks a collaborated effort
6.4.4 DRIVER
6.4.4.1 Increase in the incidence of diseases spurs the growth of the diagnostics market
6.4.5 RESTRAINT
6.4.5.1 The “interest-information” restricts growth of molecular diagnostics
6.4.6 MOLECULAR DIAGNOSTICS IN MAJOR INDICATIONS
6.4.6.1 Oncology
6.4.6.2 Cardiology
6.4.6.3 Neurology
6.4.6.4 Other treatment areas
6.4.7 BIOMARKERS IN DIAGNOSTICS
6.4.8 BENEFITS OF MOLECULAR DIAGNOSTICS

7 BIOMARKERS INDICATION MARKET
7.1 INTRODUCTION
7.2 ONCOLOGY BIOMARKERS MARKET
7.2.1 ONCOLOGY BIOMARKERS DISCOVERY MARKET
7.2.1.1 Genomics
7.2.1.2 Proteomics
7.2.1.3 Metabolomics
7.2.1.4 Transcriptomics
7.2.1.5 Other Omics
7.2.1.6 Imaging
7.2.2 DRUG DISCOVERY & DEVELOPMENT
7.2.3 CANCER TYPES
7.2.3.1 Ovarian Cancer
7.2.3.2 Breast Cancer
7.2.3.3 Bladder Cancer
7.2.3.4 Cervical Cancer
7.2.3.5 Prostate Cancer
7.2.3.6 Lung Cancer
7.2.3.7 Colorectal Cancer
7.3 CARDIOLOGY BIOMARKERS MARKET
7.3.1 CARDIOLOGY BIOMARKERS DISCOVERY MARKET
7.3.1.1 Genomics
7.3.1.2 Proteomics
7.3.1.3 Metabolomics
7.3.1.4 Transcriptomics
7.3.1.5 Imaging
7.3.1.6 Bioinformatics
7.3.2 DRUG DISCOVERY & DEVELOPMENT
7.3.3 CARDIAC MARKERS, BY DISEASE TYPES
7.3.3.1 Acute Coronary Syndrome
7.3.3.2 Coronary artery disease
7.3.3.3 Stroke
7.3.4 CARDIOLOGY BIOMARKERS USED IN THE MARKET
7.4 NEUROLOGY BIOMARKERS MARKET
7.4.1 NEUROLOGY BIOMARKERS DISCOVERY MARKET
7.4.1.1 Omics technologies
7.4.1.2 Imaging Technologies
7.4.2 DRUG DISCOVERY & DEVELOPMENT
7.4.3 DISEASE TYPES
7.4.3.1 Alzheimer’s disease
7.4.3.2 Parkinson’s disease
7.4.3.3 Multiple sclerosis
7.4.3.4 Schizophrenia
7.4.3.5 Amyotrophic Lateral Sclerosis
7.4.3.6 Epilepsy
7.5 OTHER INDICATIONS BIOMARKERS MARKET
7.5.1 OTHER INDICATION BIOMARKERS DISCOVERY MARKET
7.5.1.1 Omics technologies
7.5.1.2 Imaging technologies
7.5.2 DRUG DISCOVERY & DEVELOPMENT
7.6 DISEASE TYPES
7.6.1 HIV
7.6.1.1 Immunological & Virological Markers in HIV Infection
7.7 RENAL FAILURE
7.8 ARTHRITIS
7.9 TUBERCULOSIS
7.10 DIABETES

8 GEOGRAPHICAL ANALYSIS
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.3 EUROPE
8.4 ASIA
8.5 ROW

9 COMPETITIVE LANDSCAPE
9.1 KEY STRATEGIES
9.2 MERGERS & ACQUISITIONS
9.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES
9.4 NEW PRODUCTS LAUNCH
9.5 OTHER DEVELOPMENTS

10 COMPANY PROFILES
10.1 ABBOTT LABORATORIES
10.1.1 OVERVIEW
10.1.2 FINANCIALS
10.1.3 PRODUCTS & SERVICES
10.1.4 STRATEGY
10.1.5 DEVELOPMENTS
10.2 ABCODIA LTD
10.2.1 OVERVIEW
10.2.2 FINANCIALS
10.2.3 PRODUCTS & SERVICES
10.2.4 STRATEGY
10.2.5 DEVELOPMENTS
10.3 AFFYMETRIX INC
10.3.1 OVERVIEW
10.3.2 FINANCIALS
10.3.3 PRODUCTS & SERVICES
10.3.4 STRATEGY
10.3.5 DEVELOPMENTS
10.4 AGILENT TECHNOLOGIES INC
10.4.1 OVERVIEW
10.4.2 FINANCIALS
10.4.3 PRODUCTS & SERVICES
10.4.4 STRATEGY
10.4.5 DEVELOPMENTS
10.5 AMGEN INC
10.5.1 OVERVIEW
10.5.2 FINANCIALS
10.5.3 PRODUCTS & SERVICES
10.5.4 STRATEGY
10.5.5 DEVELOPMENT
10.6 ASTRAZENECA PLC
10.6.1 OVERVIEW
10.6.2 FINANCIALS
10.6.3 PRODUCTS & SERVICES
10.6.4 STRATEGY
10.6.5 DEVELOPMENTS
10.7 AUGUREX LIFE SCIENCES CORP
10.7.1 OVERVIEW
10.7.2 FINANCIALS
10.7.3 PRODUCTS & SERVICES
10.7.4 STRATEGY
10.7.5 DEVELOPMENTS
10.8 AUSHON BIOSYSTEMS INC
10.8.1 OVERVIEW
10.8.2 FINANCIALS
10.8.3 PRODUCTS & SERVICES
10.8.4 STRATEGY
10.8.5 DEVELOPMENTS
10.9 BAYER AG
10.9.1 OVERVIEW
10.9.2 FINANCIALS
10.9.3 PRODUCTS & SERVICES
10.9.4 STRATEGY
10.9.5 DEVELOPMENTS
10.1 BECKMAN COULTER INC
10.10.1 OVERVIEW
10.10.2 FINANCIALS
10.10.3 PRODUCTS & SERVICES
10.10.4 STRATEGY
10.10.5 DEVELOPMENTS
10.11 BGI
10.11.1 OVERVIEW
10.11.2 FINANCIALS
10.11.3 PRODUCTS & SERVICES
10.11.4 STRATEGY
10.11.5 DEVELOPMENTS
10.12 BIOCRATES LIFE SCIENCES AG
10.12.1 OVERVIEW
10.12.2 FINANCIALS
10.12.3 PRODUCTS & SERVICES
10.12.4 STRATEGY
10.12.5 DEVELOPMENTS
10.13 BIOMARKERS STRATEGIES
10.13.1 OVERVIEW
10.13.2 FINANCIALS
10.13.3 PRODUCTS & SERVICES
10.13.4 STRATEGY
10.13.5 DEVELOPMENTS
10.14 BIOSYSTEMS INTERNATIONAL
10.14.1 OVERVIEW
10.14.2 FINANCIALS
10.14.3 PRODUCTS & SERVICES
10.14.4 STRATEGY
10.14.5 DEVELOPMENTS
10.15 BRISTOL-MYERS SQUIBB
10.15.1 OVERVIEW
10.15.2 FINANCIALS
10.15.3 PRODUCTS & SERVICES
10.15.4 STRATEGY
10.15.5 DEVELOPMENTS
10.16 CRESCENDO BIOSCIENCE
10.16.1 OVERVIEW
10.16.2 FINANCIALS
10.16.3 PRODUCTS & SERVICES
10.16.4 STRATEGY
10.16.5 DEVELOPMENTS
10.17 EISAI CO. LTD.
10.17.1 OVERVIEW
10.17.2 FINANCIALS
10.17.3 PRODUCTS & SERVICES
10.17.4 STRATEGY
10.17.5 DEVELOPMENTS
10.18 EPIONTIS GMBH
10.18.1 OVERVIEW
10.18.2 FINANCIALS
10.18.3 PRODUCTS & SERVICES
10.18.4 DEVELOPMENTS
10.19 EPISTEM HOLDINGS PLC
10.19.1 OVERVIEW
10.19.2 FINANCIALS
10.19.3 PRODUCTS & SERVICES
10.19.4 STRATEGY
10.19.5 DEVELOPMENTS
10.20 EUROGENTEC S.A.
10.20.1 OVERVIEW
10.20.2 FINANCIALS
10.20.3 PRODUCTS & SERVICES
10.20.4 STRATEGY
10.20.5 DEVELOPMENTS
10.21 EVOTEC AG
10.21.1 OVERVIEW
10.21.2 FINANCIALS
10.21.3 PRODUCTS & SERVICES
10.21.4 STRATEGY
10.21.5 DEVELOPMENTS
10.22 GLAXOSMITHKLINE PLC
10.22.1 OVERVIEW
10.22.2 FINANCIALS
10.22.3 PRODUCTS & SERVICES
10.22.4 STRATEGY
10.22.5 DEVELOPMENTS
10.23 IPSEN
10.23.1 OVERVIEW
10.23.2 FINANCIALS
10.23.3 PRODUCTS & SERVICES
10.23.4 STRATEGY
10.23.5 DEVELOPMENTS
10.24 JOHNSON & JOHNSON
10.24.1 OVERVIEW
10.24.2 FINANCIALS
10.24.3 PRODUCTS & SERVICES
10.24.4 STRATEGY
10.24.5 DEVELOPMENTS
10.25 MERCK & CO.
10.25.1 OVERVIEW
10.25.2 FINANCIALS
10.25.3 PRODUCTS & SERVICES
10.25.4 STRATEGY
10.25.5 DEVELOPMENTS
10.26 MICROMEDIC TECHNOLOGIES LTD
10.26.1 OVERVIEW
10.26.2 PRODUCTS & SERVICES
10.26.3 STRATEGY
10.26.4 DEVELOPMENTS
10.27 MYRIAD GENETICS INC
10.27.1 OVERVIEW
10.27.2 FINANCIALS
10.27.3 PRODUCTS & SERVICES
10.27.4 STRATEGY
10.27.5 DEVELOPMENTS
10.28 NEXTGEN SCIENCES INC
10.28.1 OVERVIEW
10.28.2 FINANCIALS
10.28.3 PRODUCTS & SERVICES
10.28.4 STRATEGY
10.28.5 DEVELOPMENTS
10.29 NOVARTIS INTERNATIONAL AG
10.29.1 OVERVIEW
10.29.2 FINANCIALS
10.29.3 PRODUCTS & SERVICES
10.29.4 STRATEGY
10.29.5 DEVELOPMENTS
10.30 OCIMUM BIOSOLUTIONS LTD
10.30.1 OVERVIEW
10.30.2 FINANCIALS
10.30.3 PRODUCTS & SERVICES
10.30.4 STRATEGY
10.30.5 DEVELOPMENTS
10.31 PFIZER INC
10.31.1 OVERVIEW
10.31.2 FINANCIALS
10.31.3 PRODUCTS & SERVICES
10.31.4 STRATEGY
10.31.5 DEVELOPMENTS
10.32 PRONOTA NV
10.32.1 OVERVIEW
10.32.2 FINANCIALS
10.32.3 PRODUCTS & SERVICES
10.32.4 STRATEGY
10.32.5 DEVELOPMENTS
10.33 QUINTILES TRANSNATIONAL CORPORATION
10.33.1 OVERVIEW
10.33.2 FINANCIALS
10.33.3 PRODUCTS & SERVICES
10.33.4 STRATEGY
10.33.5 DEVELOPMENTS
10.34 QIAGEN NV
10.34.1 OVERVIEW
10.34.2 FINANCIALS
10.34.3 PRODUCTS & SERVICES
10.34.4 STRATEGY
10.34.5 DEVELOPMENTS
10.35 ROCHE DIAGNOSTICS LIMITED
10.35.1 OVERVIEW
10.35.2 FINANCIALS
10.35.3 PRODUCTS & SERVICES
10.35.4 STRATEGY
10.35.5 DEVELOPMENT
10.36 SANOFI-AVENTIS
10.36.1 OVERVIEW
10.36.2 FINANCIALS
10.36.3 PRODUCTS & SERVICES
10.36.4 STRATEGY
10.36.5 DEVELOPMENT
10.37 SIEMENS HEALTHCARE
10.37.1 OVERVIEW
10.37.2 FINANCIALS
10.37.3 PRODUCTS & SERVICES
10.37.4 STRATEGY
10.37.5 DEVELOPMENTS
10.38 TRANS-HIT BIOMARKERS INC
10.38.1 OVERVIEW
10.38.2 FINANCIALS
10.38.3 PRODUCTS & SERVICES
10.38.4 STRATEGY
10.38.5 DEVELOPMENTS
10.39 PACIFIC BIOMARKERS INC
10.39.1 OVERVIEW
10.39.2 FINANCIALS
10.39.3 PRODUCTS & SERVICES
10.39.4 STRATEGY
10.39.5 DEVELOPMENTS
10.40 CAPRION PROTEOMICS INC.
10.40.1 OVERVIEW
10.40.2 FINANCIALS
10.40.3 PRODUCTS & SERVICES
10.40.4 STRATEGY
10.40.5 DEVELOPMENTS
10.41 PROTEOME SCIENCES PLC
10.41.1 OVERVIEW
10.41.2 FINANCIALS
10.41.3 PRODUCTS & SERVICES
10.41.4 STRATEGY
10.41.5 DEVELOPMENTS
10.42 VERMILLION INC
10.42.1 OVERVIEW
10.42.2 FINANCIALS
10.42.3 PRODUCTS & SERVICES
10.42.4 STRATEGY
10.42.5 DEVELOPMENTS

LIST OF TABLES

TABLE 1 GLOBAL BIOMARKERS MARKET REVENUE, BY SEGMENTS, 2009-2020 ($MILLION)
TABLE 2 GLOBAL BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 3 GLOBAL BIOMARKERS DISCOVERY MARKET, BY INDICATIONS, 2009-2020 ($MILLION)
TABLE 4 BIOMARKERS DISCOVERY TECHNOLOGIES MARKET, BY GEOGRAPHY, 2009-2020 ($MILLION)
TABLE 5 GLOBAL BIOMARKERS DISCOVERY MARKET, BY IMAGING TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 6 BIOMARKERS IMAGING TECHNOLOGIES MARKET, BY GEOGRAPHY, 2009-2020 ($MILLION)
TABLE 7 GLOBAL BIOMARKERS DISCOVERY MARKET, BY OMICS TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 8 GLOBAL BIOMARKERS OMICS TECHNOLOGIES MARKET, BY INDICATIONS, 2009-2020 ($MILLION)
TABLE 9 BIOMARKERS OMICS TECHNOLOGIES MARKET, BY GEOGRAPHY, 2009-2020 ($MILLION)
TABLE 10 GLOBAL PROTEOMICS BIOMARKERS MARKET, BY INDICATIONS, 2009-2020 ($MILLION)
TABLE 11 GLOBAL GENOMICS BIOMARKERS MARKET, BY INDICATIONS, 2009-2020 ($MILLION)
TABLE 12 GLOBAL TRANSCRIPTOMICS BIOMARKERS MARKET, BY INDICATIONS, 2009-2020 ($MILLION)
TABLE 13 GLOBAL METABOLOMICS BIOMARKERS MARKET, BY INDICATIONS, 2009-2020 ($MILLION)
TABLE 14 GLOBAL BIOMARKERS BIOINFORMATICS MARKET, BY INDICATIONS, 2009-2020 ($MILLION)
TABLE 15 BIOMARKERS BIOINFORMATICS MARKET, BY GEOGRAPHY, 2009-2020 ($MILLION)
TABLE 16 GLOBAL BIOMARKERS MARKET, BY APPLICATIONS, 2009-2020 ($MILLION)
TABLE 17 GLOBAL BIOMARKERS APPLICATION MARKET, BY INDICATIONS, 2009-2020 ($MILLION)
TABLE 18 BIOMARKERS APPLICATION MARKET, BY GEOGRAPHY, 2009-2020 ($MILLION)
TABLE 19 GLOBAL BIOMARKERS DRUG DISCOVERY & DEVELOPMENT PROCESS MARKET, BY INDICATIONS, 2009-2020 ($MILLION)
TABLE 20 BIOMARKERS DRUG DISCOVERY & DEVELOPMENT PROCESS MARKET, BY GEOGRAPHY, 2009-2020 ($MILLION)
TABLE 21 GLOBAL BIOMARKERS APPLICATION MARKET, BY PHASES IN DRUG DISCOVERY & DEVELOPMENT PROCESS, 2009-2020 ($MILLION)
TABLE 22 GLOBAL BIOMARKERS PRECLINICAL STUDY MARKET, BY VARIOUS INDICATIONS, 2009-2020 ($MILLION)
TABLE 23 GLOBAL BIOMARKERS PHASE I MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009-2020 ($MILLION)
TABLE 24 GLOBAL BIOMARKERS PHASE II MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009-2020 ($MILLION)
TABLE 25 GLOBAL BIOMARKERS PHASE III MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009-2020 ($MILLION)
TABLE 26 GLOBAL BIOMARKERS PHASE IV MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009-2020 ($MILLION)
TABLE 27 PERSONALIZED MEDICINE(PM) USING BIOMARKERS IN CURRENT DRUG LABELS
TABLE 28 GLOBAL BIOMARKERS PERSONALIZED MEDICINE MARKET, BY INDICATIONS, 2009-2020 ($MILLION)
TABLE 29 BIOMARKERS PERSONALIZED MEDICINE MARKET, BY GEOGRAPHY, 2009-2020 ($MILLION)
TABLE 30 GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY INDICATIONS, 2009-2020 ($MILLION)
TABLE 31 MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY, 2009-2020 ($MILLION)
TABLE 32 GLOBAL BIOMARKERS MARKET, BY INDICATIONS, 2009-2020 ($MILLION)
TABLE 33 GLOBAL ONCOLOGY BIOMARKERS MARKET, BY SEGMENTS, 2009-2020 ($MILLION)
TABLE 34 GLOBAL ONCOLOGY BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 35 GLOBAL ONCOLOGY BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 36 GLOBAL ONCOLOGY BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 37 GLOBAL ONCOLOGY BIOMARKERS MARKET, BY PHASES, 2009-2020 ($MILLION)
TABLE 38 GLOBAL ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009-2020 ($MILLION)
TABLE 39 ONCOLOGY BIOMARKERS MARKET, BY GEOGRAPHY, 2009-2020 ($MILLION)
TABLE 40 GLOBAL CARDIOLOGY BIOMARKERS MARKET REVENUE, BY SEGMENTS, 2009-2020 ($MILLION)
TABLE 41 GLOBAL CARDIOLOGY BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 42 GLOBAL CARDIOLOGY BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 43 GLOBAL CARDIOLOGY BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 44 GLOBAL CARDIOLOGY BIOMARKERS MARKET, BY PHASES, 2009-2020 ($MILLION)
TABLE 45 GLOBAL CARDIOLOGY BIOMARKERS MARKET, BY INDICATIONS, 2009-2020 ($MILLION)
TABLE 46 COMMONLY USED CARDIAC BIOMARKERS TESTS
TABLE 47 BIOMARKERS TESTS USED FOR PROGNOSIS
TABLE 48 CARDIAC MARKERS MARKET REVENUE, BY GEOGRAPHY, 2009-2020 ($MILLION)
TABLE 49 GLOBAL NEUROLOGY BIOMARKERS MARKET, BY SEGMENTS, 2009-2020 ($MILLION)
TABLE 50 GLOBAL NEUROLOGY BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 51 GLOBAL NEUROLOGY BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 52 GLOBAL NEUROLOGY BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 53 GLOBAL NEUROLOGY BIOMARKERS MARKET, BY PHASES, 2009-2020 ($MILLION)
TABLE 54 GLOBAL NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009– 2020 ($MILLION)
TABLE 55 NEUROLOGY BIOMARKERS MARKET, BY GEOGRAPHY, 2009-2020 ($MILLION)
TABLE 56 GLOBAL OTHER INDICATIONS BIOMARKERS MARKET, BY SEGMENTS, 2009-2020 ($MILLION)
TABLE 57 GLOBAL OTHER INDICATIONS BIOMARKERS MARKET REVENUE, BY DISCOVERY TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 58 GLOBAL OTHER INDICATIONS BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 59 GLOBAL OTHER INDICATIONS BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 60 GLOBAL OTHER INDICATIONS BIOMARKERS MARKET, BY PHASES, 2009-2020 ($MILLION)
TABLE 61 GLOBAL OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009-2020 ($MILLION)
TABLE 62 HIV BIOMARKERS
TABLE 63 RENAL BIOMARKERS
TABLE 64 OTHER INDICATIONS MARKET REVENUE, BY GEOGRAPHY, 2009-2020 ($MILLION)
TABLE 65 BIOMARKERS MARKET REVENUE, BY GEOGRAPHY, 2009-2020 ($BILLION)
TABLE 66 NORTH AMERICA: BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 67 NORTH AMERICA: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 68 NORTH AMERICA: BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 69 NORTH AMERICA: BY APPLICATIONS, 2009-2020 ($MILLION)
TABLE 70 NORTH AMERICA: BY DRUG DISCOVERY & DEVELOPMENT, 2009-2020 ($MILLION)
TABLE 71 NORTH AMERICA: BY INDICATIONS, 2009-2020 ($MILLION)
TABLE 72 NORTH AMERICA: ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009-2020 ($MILLION)
TABLE 73 NORTH AMERICA: BIOMARKERS MARKET, CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009-2020 ($MILLION)
TABLE 74 NORTH AMERICA: NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009-2020 ($MILLION)
TABLE 75 NORTH AMERICA: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009-2020 ($MILLION)
TABLE 76 EUROPE: BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 77 EUROPE: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 78 EUROPE: BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 79 EUROPE: BY APPLICATIONS, 2009-2020 ($MILLION)
TABLE 80 EUROPE: BY DRUG DISCOVERY & DEVELOPMENT, 2009-2020 ($MILLION)
TABLE 81 EUROPE: BY INDICATIONS, 2009-2020 ($MILLION)
TABLE 82 EUROPE: BIOMARKERS MARKET, ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009-2020 ($MILLION)
TABLE 83 EUROPE: CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009-2020 ($MILLION)
TABLE 84 EUROPE: NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009-2020 ($MILLION)
TABLE 85 EUROPE: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009-2020 ($MILLION)
TABLE 86 ASIA: BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 87 ASIA: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 88 ASIA: BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 89 ASIA: BY APPLICATIONS, 2009-2020 ($MILLION)
TABLE 90 ASIA: BY DRUG DISCOVERY & DEVELOPMENT, 2009-2020 ($MILLION)
TABLE 91 ASIA: BY INDICATIONS, 2009-2020 ($MILLION)
TABLE 92 ASIA: ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009-2020 ($MILLION)
TABLE 93 ASIA: CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009-2020 ($MILLION)
TABLE 94 ASIA: BIOMARKERS MARKET, NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009-2020 ($MILLION)
TABLE 95 ASIA: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009-2020 ($MILLION)
TABLE 96 ROW: BIOMARKERS MARKET, BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 97 ROW: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 98 ROW: BY IMAGING TECHNOLOGIES, 2009-2020 ($MILLION)
TABLE 99 ROW: BY APPLICATIONS, 2009-2020 ($MILLION)
TABLE 100 ROW: BY DRUG DISCOVERY & DEVELOPMENT, 2009-2020 ($MILLION)
TABLE 101 ROW: BIOMARKERS MARKET, BY INDICATIONS, 2009-2020 ($MILLION)
TABLE 102 ROW: ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009-2020 ($MILLION)
TABLE 103 ROW: BIOMARKERS MARKET, CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009-2020 ($MILLION)
TABLE 104 ROW: NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009-2020 ($MILLION)
TABLE 105 ROW: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009-2020 ($MILLION)
TABLE 106 MERGERS & ACQUISITIONS (JANUARY 2009-DECEMBER 2011)
TABLE 107 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (JANUARY 2009-DECEMBER 2011)
TABLE 108 NEW PRODUCTS LAUNCH (JANUARY 2009-DECEMBER 2011)
TABLE 109 OTHER DEVELOPMENTS (JANUARY 2009-DECEMBER 2011)
TABLE 110 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 111 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS, 2008-2010 ($MILLION)
TABLE 112 ABBOTT LABORATORIES: REVENUE, BY GEOGRAPHY, 2008-2010 ($MILLION)
TABLE 113 AFFYMETRIX INC: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 114 AFFYMETRIX INC: TOTAL REVENUE, BY SEGMENTS, 2008-2010 ($MILLION)
TABLE 115 AFFYMETRIX INC: REVENUE, BY GEOGRAPHY, 2008-2010 ($MILLION)
TABLE 116 AGILENT TECHNOLOGIES INC: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 117 AGILENT TECHNOLOGIES INC: TOTAL REVENUE, BY SEGMENTS, 2008-2010 ($MILLION)
TABLE 118 AGILENT TECHNOLOGIES INC: REVENUE, BY GEOGRAPHY, 2008-2010 ($MILLION)
TABLE 119 AMGEN INC: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 120 AMGEN INC: REVENUE, BY GEOGRAPHY, 2008-2010 ($MILLION)
TABLE 121 ASTRAZENECA PLC: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 122 ASTRAZENECA PLC: TOTAL REVENUE, BY SEGMENTS, 2008-2010 ($MILLION)
TABLE 123 ASTRAZENECA PLC: REVENUE, BY GEOGRAPHY, 2008-2010 ($MILLION)
TABLE 124 BAYER AG: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 125 BAYER AG: TOTAL REVENUE, BY SEGMENTS, 2008-2010 ($MILLION)
TABLE 126 BAYER AG: REVENUE, BY GEOGRAPHY, 2008-2010 ($MILLION)
TABLE 127 BECKMAN COULTER INC: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 128 BECKMAN COULTER INC: TOTAL REVENUE, BY SEGMENTS, 2008-2010 ($MILLION)
TABLE 129 BECKMAN COULTER INC: REVENUE, BY GEOGRAPHY, 2008-2010 ($MILLION)
TABLE 130 BRISTOL-MYERS SQUIBB: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 131 BRISTOL-MYERS SQUIBB: TOTAL REVENUES, BY SEGMENTS, 2008-2010 ($MILLION)
TABLE 132 BRISTOL-MYERS SQUIBB: REVENUE, BY GEOGRAPHY, 2008-2010 ($MILLION)
TABLE 133 EISAI CO. LTD: TOTAL REVENUE AND R&D EXPENSES, 2009-2011 ($MILLION)
TABLE 134 EISAI CO. LTD: TOTAL REVENUES, BY SEGMENTS, 2009-2011 ($MILLION)
TABLE 135 EISAI CO. LTD: REVENUE, BY GEOGRAPHY, 2009-2011 ($MILLION)
TABLE 136 EPISTEM HOLDINGS PLC: TOTAL REVENUE AND R&D EXPENSES, 2009-2011 ($MILLION)
TABLE 137 EPISTEM HOLDINGS PLC: TOTAL REVENUE, BY SEGMENTS, 2009-2011 ($MILLION)
TABLE 138 EPISTEM HOLDINGS PLC: REVENUE, BY GEOGRAPHY, 2009-2011 ($MILLION)
TABLE 139 EVOTEC AG: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 140 EVOTEC AG: REVENUE, BY GEOGRAPHY, 2008-2010 ($MILLION)
TABLE 141 GLAXOSMITHKLINE PLC: TOTAL REVENUE AND R&D EXPENSES, 2008-2011 ($MILLION)
TABLE 142 GLAXOSMITHKLINE PLC: TOTAL REVENUE, BY SEGMENTS, 2008-2011 ($MILLION)
TABLE 143 GLAXOSMITHKLINE PLC: REVENUE FOR PHARMACEUTICAL SEGMENT, BY GEOGRAPHY, 2008-2011 ($MILLION)
TABLE 144 IPSEN: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 145 IPSEN: TOTAL REVENUE, BY SEGMENTS, 2008-2010 ($MILLION)
TABLE 146 IPSEN: REVENUE, BY GEOGRAPHY, 2008-2010 ($MILLION)
TABLE 147 JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 148 JOHNSON & JOHNSON: TOTAL REVENUE, BY SEGMENTS, 2008 -2010 ($MILLION)
TABLE 149 MEDICAL DEVICES & DIAGNOSTICS SEGMENT REVENUE, 2008-2010 ($MILLION)
TABLE 150 JOHNSON & JOHNSON: REVENUE, BY GEOGRAPHY, 2008-2010 ($MILLION)
TABLE 151 MERCK & CO: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 152 MERCK & CO: TOTAL REVENUES, BY SEGMENTS, 2008-2010 ($MILLION)
TABLE 153 MERCK & CO: REVENUE, BY GEOGRAPHY, 2008-2010 ($MILLION)
TABLE 154 MYRIAD GENETICS INC: TOTAL REVENUE AND R&D EXPENSES, 2009-2011 ($MILLION)
TABLE 155 MYRIAD GENETICS INC: TOTAL REVENUE, BY SEGMENTS, 2009-2011 ($MILLION)
TABLE 156 NEXTGEN GROUP PLC: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 157 NEXTGEN GROUP PLC: REVENUE, BY GEOGRAPHY, 2008-2010 ($MILLION)
TABLE 158 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 159 NOVARTIS INTERNATIONAL AG: TOTAL REVENUES, BY SEGMENTS, 2008-2010 ($MILLION)
TABLE 160 NOVARTIS INTERNATIONAL AG: REVENUE, BY GEOGRAPHY, 2008-2010 ($MILLION)
TABLE 161 PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 162 PFIZER INC: TOTAL REVENUE, BY SEGMENTS, 2008-2010 ($MILLION)
TABLE 163 PFIZER INC: REVENUE, BY GEOGRAPHY, 2008-2010 ($MILLION)
TABLE 164 QIAGEN N.V: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 165 QIAGEN N.V.: TOTAL REVENUE, BY SEGMENTS, 2008-2010 ($MILLION)
TABLE 166 QIAGEN N.V.: GEOGRAPHIC REVENUES, 2008-2010 ($MILLION)
TABLE 167 ROCHE: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 168 ROCHE: TOTAL REVENUE, BY SEGMENTS, 2008-2010 ($MILLION)
TABLE 169 SANOFI-AVENTIS: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 170 SANOFI-AVENTIS: TOTAL REVENUE, BY SEGMENTS, 2008-2010 ($MILLION)
TABLE 171 SANOFI-AVENTIS: REVENUE, BY GEOGRAPHY, 2008-2010 ($MILLION)
TABLE 172 SIEMENS: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 173 SIEMENS: TOTAL REVENUE, BY SEGMENTS, 2008-2010 ($MILLION)
TABLE 174 SIEMENS: REVENUE, BY GEOGRAPHY, 2008-2010 ($MILLION)
TABLE 175 PROTEOME SCIENCES PLC: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 176 PROTEOME SCIENCES PLC: REVENUE, BY GEOGRAPHY, 2008-2010 ($MILLION)
TABLE 177 VERMILLION INC: TOTAL REVENUE AND R&D EXPENSES, 2008-2010 ($MILLION)
TABLE 178 VERMILLION INC: TOTAL REVENUE, BY SEGMENTS, 2008-2010 ($MILLION)


LIST OF FIGURES

FIGURE 1 OVERVIEW OF BIOMARKERS MARKET
FIGURE 2 LIFE CYCLE OF A BIOMARKERS
FIGURE 3 BIOMARKERS MARKET
FIGURE 4 LEVEL OF IMPACT OF CHALLENGES
FIGURE 5 BIOMARKERS DISCOVERY PROCESS
FIGURE 6 BIOMARKERS DISCOVERY MARKET, 2011
FIGURE 7 OMICS TECHNOLOGIES & THE CENTRAL DOGMA
FIGURE 8 BIOMARKERS DISCOVERY MARKET, BY OMICS TECHNOLOGIES, 2011
FIGURE 9 THE CENTRAL ROLE OF MASS SPECTROMETRY IN PROTEOMICS
FIGURE 10 BIOMARKERS DISCOVERY USING 2-D DIGE & MS
FIGURE 11 TRANSCRIPTOMICS BIOMARKERS DISCOVERY
FIGURE 12 BIOINFORMATICS MICROARRAY TOOLS
FIGURE 13 CLUSTER ANALYSIS OF OMICS DATA FOR BIOMARKERS DISCOVERY
FIGURE 14 BIOMARKERS SERVICES MARKET, BY SEGMENTS (%)
FIGURE 15 FLOW OF CLINICAL BIOMARKERS SERVICES
FIGURE 16 DRUG DISCOVERY & DEVELOPMENT PROCESS
FIGURE 17 BIOMARKERS DISCOVERY, BY INDICATIONS, 2011
FIGURE 18 KEY GROWTH STRATEGIES (JANUARY 2009-DECEMBER 2011)

★調査レポート[世界のバイオマーカー市場] ( Biomarkers Market - ([Discovery Technologies - Proteomics, Genomics, Imaging, Bioinformatics], Validation Services, Applications [drug development, personalized medicine], Diseases [Oncology, Cardiology, Neurology]) - Global Trends & Forecasts (2013-2018) / BT 2120) 販売に関する免責事項
[世界のバイオマーカー市場] ( Biomarkers Market - ([Discovery Technologies - Proteomics, Genomics, Imaging, Bioinformatics], Validation Services, Applications [drug development, personalized medicine], Diseases [Oncology, Cardiology, Neurology]) - Global Trends & Forecasts (2013-2018) / BT 2120) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆